A Study to Evaluate the Efficacy of ELAPR002f in Females and Males With Atrophic Acne Scars

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

March 23, 2018

Study Completion Date

September 11, 2018

Conditions

Atrophic Acne Scar

Interventions

DEVICE

ELAPR002f

30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid

DEVICE

Saline

Saline control

Trial Locations (1)

Hammersmith Medicines Research, London

All Listed Sponsors

lead

Elastagen Pty Ltd

INDUSTRY

NCT03056235 - A Study to Evaluate the Efficacy of ELAPR002f in Females and Males With Atrophic Acne Scars | Biotech Hunter | Biotech Hunter